SCHEMBL6698640

SCHEMBL6698640

O=C(Cc1cscc1NS(=O)(=O)c1ccc(-c2ccc(OC(F)(F)F)cc2)cc1)N1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
PKM P14618 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
EPHX2 P34913 1/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6626941 0.86 ALDH1A1 (0.42) KMT2ALMNAGAAL3MBTL1ALDH1A1
SCHEMBL6613171 0.86 MAPT (0.53) KMT2ALMNAGAAL3MBTL1MMP2
SCHEMBL7080427 0.86 KMT2A (0.47) KMT2ALMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL6624850 0.85 HSD11B1 (0.45) KMT2ALMNAGAAL3MBTL1ALDH1A1
SCHEMBL6623941 0.84 ALDH1A1 (0.41) KMT2ALMNAGAAL3MBTL1ALDH1A1
SCHEMBL6627199 0.84 KMT2A (0.45) KMT2ALMNAGAAL3MBTL1MMP1
SCHEMBL6695594 0.83 PKM (0.42) KMT2ALMNAGAAPKMALDH1A1
SCHEMBL6616549 0.83 SMN1; SMN2 (0.48) KMT2ALMNAGAAL3MBTL1MMP1
SCHEMBL6627742 0.83 ALDH1A1 (0.55) KMT2ALMNAGAAL3MBTL1MMP1
SCHEMBL3611317 0.82 HSD11B1 (0.56) KMT2ALMNAGAAL3MBTL1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 KMT2A 3247/4885LMNA 1976/4885GAA 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.